Dr. Dale Bredesen’s findings differ from previous curative models based on plaques building up in the brain. He discovered that amyloid beta peptide, the source of plaques, has a normal function that is being hijacked, and thus increased, resulting in plaques associated with memory loss and confusion. For Bredesen, the plaque was not the cause, or rather the symptomatic cause had multiple causes. Bredesen discovered the roots of the previously cited cause.
The new Alzheimer’s disease cure that reverses memory loss and confusion is far less complicated than it sounds. UCLA Newsroom relates the story of one patient. The female subject had a very demanding job and yet found herself getting lost on the way home. She was forgetting her route and her ability to map the course was severely impaired. Some but not all of Dr. Dale Bredesen’s treatments were incorporated. Here is her prescription as listed by UCLA Newsroom.
- eliminating all simple carbohydrates, gluten, and processed food from her diet, and eating more vegetables, fruits, and non-farmed fish
- meditating twice a day and beginning yoga to reduce stress
- sleeping seven to eight hours per night, up from four to five
- taking melatonin, methylcobalamin, vitamin D3, fish oil, and coenzyme Q10 each day
- optimizing oral hygiene using an electric flosser and electric toothbrush
- reinstating hormone replacement therapy, which had previously been discontinued
- fasting for a minimum of 12 hours between dinner and breakfast, and for a minimum of three hours between dinner and bedtime
- exercising for a minimum of 30 minutes, four to six days per week
We support practitioners and their patients by providing the latest research results that are regularly updated, providing dynamic, evolving solutions for cognitive decline and risk for cognitive decline.
This medical information includes:
- The Bredesen 3.0 protocol (and subsequent versions), a personalized, comprehensive protocol for the reversal of cognitive decline (Bredesen, Aging 2014; Bredesen, Aging 2015; Bredesen, Aging 2016) in individuals with early Alzheimer’s disease, mild cognitive impairment (MCI), subjective cognitive impairment (SCI), or at risk for cognitive decline.
- Software that evaluates large data sets of genomic, biochemical, functional, and radiological data with respect the major types of Alzheimer’s disease (Bredesen, Aging 2015) and other conditions.
- Software that determines which major type of Alzheimer’s Disease each participant has.
- Information for coaches, patients, nutritionists, physical therapists, and other team members.
- Optimal tests for evaluation, treatment, and follow-up tracking of people with cognitive decline, at risk for cognitive decline, or those interested in improving cognition.
- We provide a list of tests that identify factors contributing to cognitive decline.
- Training on the ReCODE 3.0 software.
- Become a certified practitioner of the Bredesen 3.0 protocol by signing up for an upcoming course.
- We provide intensive (immersion) programs for their spouses and/or significant others who may want to participate.